...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Brachytherapy >Delineating the relationship between Point A prescription dose and pelvic lymph node doses in intracavitary high-dose-rate brachytherapy treatment of cervical cancer for use in low- and middle-income countries
【24h】

Delineating the relationship between Point A prescription dose and pelvic lymph node doses in intracavitary high-dose-rate brachytherapy treatment of cervical cancer for use in low- and middle-income countries

机译：描绘点处方剂量和盆腔淋巴结剂中的宫颈癌颈椎治疗中的处方剂量和盆腔淋巴结剂量，用于低收入和中等收入国家

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Purpose To define the relationship between the Point A prescription dose and the dose delivered to various pelvic lymph node groups during high-dose-rate (HDR) brachytherapy treatment of cervical cancer. In less developed countries, brachytherapy is often done without three-dimensional image guidance, instead relying on plain radiography and prescription to Point A. A defined relationship between Point A dose and lymph node doses would help physicians in these health care settings to more accurately estimate nodal doses. Methods AND MATERIALS Treatment data from 50 fractions of HDR brachytherapy of cervical cancer were reviewed, the pelvic lymph nodes were contoured, and dose–volume histogram parameters were obtained. Dose–volume histogram parameters for each contour were normalized as a percentage of the corresponding Point A dose. All nodal groups were divided into left and right sides, except the presacral nodal group. Results AND CONCLUSIONS Mean Point A doses were bilateral (Bil) 5.92?Gy?±?0.58, left (L) 5.93?±?0.59, and right (R) 5.92?±?0.59. Mean normalized D90 values for the various lymph node groups were as follows—obturator: Bil 20.3%?±?4.5, L 20.5%?±?4.4, and R 20.2%?±?5.2; external iliac: Bil 9.5%?±?2.9, L 10.0%?±?3.1, and R 9.5%?±?3.0; internal iliac: Bil 12.2%?±?3.5, L 12.1%?±?3.4, and R 12.9%?±?4.7; common iliac: Bil 4.3%?±?1.6, L 4.3%?±?1.6, and R 4.3%?±?1.7; and presacral: 8.7%?±?3.4. These relationships can serve as a useful tool for evaluating lymph node doses during HDR brachytherapy of cervical cancer in facilities performing two-dimensional treatment planning and those with limited resources.
机译：摘要目的是在宫颈癌的高剂量率（HDR）近距离治疗期间定义某个处方剂量与递送至各种盆腔淋巴结组的剂量的关系。在不欠发达的国家，近距离放射治疗通常没有三维图像引导，而是依赖于普通的放射线照相和处方点A.点的定义关系，剂量和淋巴结剂量会有助于这些医疗保健环境中的医生以更准确地估计节点剂量。方法和材料治疗来自50分数的宫颈癌HDR近距离放射治疗的数据，盆腔淋巴结均呈现，获得剂量血液曲线参数。每个轮廓的剂量直方图参数标准化为剂量的相应点的百分比。除妊娠结节组外，所有节点组分为左侧和右侧。结果和结论意味着一剂剂量是双侧（BIL）5.92？GY？±±0.58，左（L）5.93？±0.59，右（R）5.92？0.59。平均各种淋巴结组的归一化D90值如下 - 闭孔器：BIL 20.3％？±4.5，L 20.5％？±4.4和R 20.2％？±5.2;外部髂骨：BIL 9.5％？±2.9，L 10.0％？±3.1和R.5％？±3.0;内部髂髂12.2％？±3.5，L 12.1％？±3.4，r 12.9％？±4.7;常见的髂髂4.3％？±1.6，1 4.3％？±1.6，r 4.3％？±1.7;和急剧：8.7％？±3.4。这些关系可以作为在宫颈癌HDR近距离放射治疗期间评估淋巴结剂量的有用工具，该宫颈癌在执行二维治疗规划和资源有限的设施中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号